Notis McConarty Edward lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.7% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 55,037 shares of the company’s stock after selling 410 shares during the period. Johnson & Johnson accounts for approximately 4.7% of Notis McConarty Edward’s holdings, making the stock its largest position. Notis McConarty Edward’s holdings in Johnson & Johnson were worth $7,281,000 at the end of the most recent quarter.
Other institutional investors have also bought and sold shares of the company. Lynch & Associates IN grew its holdings in Johnson & Johnson by 0.9% during the second quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock worth $12,397,000 after purchasing an additional 841 shares during the period. Oakbrook Investments LLC grew its holdings in Johnson & Johnson by 7.4% during the second quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock worth $18,008,000 after purchasing an additional 9,375 shares during the period. Trexquant Investment LP bought a new position in Johnson & Johnson during the first quarter worth about $1,731,000. Bollard Group LLC grew its holdings in Johnson & Johnson by 5.0% during the second quarter. Bollard Group LLC now owns 9,551 shares of the company’s stock worth $1,263,000 after purchasing an additional 459 shares during the period. Finally, Adams Diversified Equity Fund Inc. grew its holdings in Johnson & Johnson by 278.0% during the second quarter. Adams Diversified Equity Fund Inc. now owns 241,900 shares of the company’s stock worth $32,001,000 after purchasing an additional 177,900 shares during the period. Institutional investors and hedge funds own 65.90% of the company’s stock.
Shares of Johnson & Johnson (NYSE JNJ) traded up 0.58% on Friday, reaching $142.87. 1,846,486 shares of the company’s stock traded hands. The firm has a market cap of $383.46 billion, a P/E ratio of 24.85 and a beta of 0.78. The company’s 50-day moving average price is $133.48 and its 200 day moving average price is $130.63. Johnson & Johnson has a one year low of $109.32 and a one year high of $143.62.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. During the same period in the previous year, the business earned $1.68 earnings per share. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, equities analysts forecast that Johnson & Johnson will post $7.27 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.37%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s payout ratio is 58.33%.
In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the transaction, the vice president now directly owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.19% of the stock is owned by company insiders.
A number of equities analysts recently commented on the company. Jefferies Group LLC lifted their price target on Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a report on Monday. Barclays PLC lifted their price target on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “equal weight” rating in a report on Wednesday. BMO Capital Markets reiterated a “positive” rating and set a $152.00 price target (up previously from $145.00) on shares of Johnson & Johnson in a report on Wednesday. Leerink Swann restated an “outperform” rating and set a $165.00 price objective (up previously from $150.00) on shares of Johnson & Johnson in a report on Wednesday. Finally, Cowen and Company restated an “outperform” rating and set a $155.00 price objective (up previously from $147.00) on shares of Johnson & Johnson in a report on Wednesday. Five equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have given a buy rating to the stock. Johnson & Johnson has an average rating of “Hold” and a consensus price target of $141.66.
WARNING: “Notis McConarty Edward Sells 410 Shares of Johnson & Johnson (JNJ)” was posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://transcriptdaily.com/2017/10/20/notis-mcconarty-edward-sells-410-shares-of-johnson-johnson-jnj.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.